The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
FDA grants ALPN-101 an Orphan Drug Designation for the prevention and treatment of acute GvHD
On March 18, 2020, the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for ALPN-101 for the prevention and treatment of acute graft-versus-host disease (aGvHD).1
ALPN-101 is a first-in-class Fc fusion protein of a human inducible T-cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™). The drug targets inflammatory process by simultaneous inhibition of the CD28 and ICOS signaling pathways, which are involved in T-cell activation. Results in preclinical models of GvHD, and other autoimmune and inflammatory diseases, such as inflammatory arthritis, and multiple sclerosis, revealed improved efficacy of dual CD28-ICOS blockade with ALPN-101 vs single pathway blockade.2
A phase I study (NCT03748836) of ALPN-101 in healthy volunteers completed enrolment in October 2019. The initial data were presented at the American Society of Hematology annual meeting in December 2019, with more data expected in 2020. A phase I/IIb Balance study (NCT04227938) investigating ALPN-101 in patients with steroid-refractory/resistant aGvHD is currently recruiting.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content